StockNow
Calendar
Log in
U.S. Markets

Bristol Myers Squibb (BMY) announces Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis met primary endpoint

StockNow breaking-news AI analysis

Bristol Myers Squibb reported that the Phase 3 ALOFT-IPF trial met its primary endpoint, but the available headline-only record provides no results or safety details.

1 stocks
BMYBristol-Myers Squibb Co.$61.46Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Ukrainian President Zelensky says Russia attacked Ukraine following US President Trump's announcement. In the winter, if Russia does not agree to an energy ceasefire, Ukraine will respond; says Russia has violated the Trump energy ceasefire

Geopolitics

Iranian Foreign Ministry spokesperson Baghaei says exchanges of messages with the US continue via intermediaries; Tehran is still reviewing US positions and will respond via intermediaries once the review is complete

Geopolitics

Saudi-led coalition says it has detected and is tracking a drone and cruise missile threat against Saudi Arabia and is taking measures to address it, Al Arabiya reports